M Bayes, X Rabasseda, JR Prous - Methods and findings in …, 2006 - journals.prous.com Contributing Editors: P. Cole, C. Orellana, JA Vallès, RM a . Antonijoan, KP Mohana Priya,
M. Priya, V. Renuga, R. Sree Lekha, B. Priya, A. Tomillero, G. Krithiga and E. Banu Rekha. Cited by 148 - Related articles - All 9 versions
- ►diabetesjournals.org O Schmitz, B Brock, J Rungby - Diabetes, 2004 - Am Diabetes Assoc Amylin is a peptide hormone that is cosecreted with insulin from the pancreatic ß-cell and is thus
deficient in diabetic people. It inhibits glucagon secretion, delays gastric emptying, and acts as
a satiety agent. Amylin replacement could therefore possibly improve glycemic control in ... Cited by 76 - Related articles - BL Direct - All 4 versions
MC Riddle, DJ Drucker - Diabetes Care, 2006 - Am Diabetes Assoc Current therapies for type 2 diabetes are frequently associated with inadequate control of postprandial
hyperglycemia, weight gain, and, in the case of oral agents, loss of efficacy over time. A better
understanding of physiological responses to meals is leading to the development of new ... Cited by 72 - Related articles - BL Direct - All 10 versions
- ►diabetesjournals.org A Ceriello, L Piconi, L Quagliaro, Y Wang, CA … - Diabetes Care, 2005 - Am Diabetes Assoc OBJECTIVE—Oxidative stress has been shown to be increased in the postprandial period in
patients with diabetes and has been implicated in the pathogenesis of micro- and macrovascular
complications. The aim of this post hoc analysis was to assess the effects of pramlintide, ... Cited by 55 - Related articles - All 6 versions
GI Uwaifo, RE Ratner - Endocrinology and metabolism clinics of North America, 2005 - Elsevier Since the discovery of insulin by Banting and Best in the early 20th century, the clinical management
of diabetes has undergone significant changes. The last decade has been associated with an
explosion in therapeutic options for management of type 2 diabetes that has significantly ... Cited by 38 - Related articles - All 3 versions
S Edelman, S Garg, J Frias, D Maggs, Y Wang, B … - Diabetes Care, 2006 - Am Diabetes Assoc RESULTS—Baseline A1C was 8.1% for both groups and at week 29 had decreased comparably
(pramlintide −0.5% [95% CI −0.61 to −0.33]; placebo −0.5% [−0.63 to −0.35]). Pramlintide treatment
significantly reduced postprandial glucose excursions (incremental area under the curve [ ... Cited by 39 - Related articles - BL Direct - All 10 versions
GJ Ryan, LJ Jobe, R Martin - Clinical therapeutics, 2005 - Elsevier Amylin is a 37-amino acid peptide 1026 neurohormone that is cosecreted with insulin from the
pancreatic β cells in response to meals. It lowers serum glucose by decreasing glucagon
release, slowing gastric emptying, and decreasing food intake. Pramlintide, a synthetic ... Cited by 32 - Related articles - All 3 versions
MS Rendell, L Jovanovic - Metabolism, 2006 - Elsevier In healthy individuals, blood glucose levels in the fasting state are maintained by the continuous
basal-level insulin secretion. After a meal, the rise in postprandial glucose (PPG) is controlled
by the rapid pancreatic release of insulin, stimulated by both glucose and the intestinal ... Cited by 30 - Related articles - All 12 versions
CJ Bailey - Current Diabetes Reports, 2005 - Springer Introduction The term “diabesity,” meaning diabetes coupled with obesity, was popularized by
Shafrir [1]. It emphasizes the frequent coexistence and pathogenic interrelationship between
these two conditions [2]. Treatment of overweight and obese patients with type 2 diabetes ... Cited by 24 - Related articles - BL Direct - All 2 versions
